<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04005079</url>
  </required_header>
  <id_info>
    <org_study_id>2017-8704</org_study_id>
    <nct_id>NCT04005079</nct_id>
  </id_info>
  <brief_title>Pilocarpine After Combined Cataract/Trabectome Surgery</brief_title>
  <acronym>PACCT</acronym>
  <official_title>A Prospective Randomized Control Trial of Pilocarpine Use After Combined Cataract/Trabectome Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combined cataract + trabectome surgery is a surgery designed to help lower the intraocular&#xD;
      pressure (pressure in the eye) and hopefully reduce the need for topical drops, progression&#xD;
      of glaucoma, and/or further glaucoma surgeries. The purpose of this study is to assess&#xD;
      whether using pilocarpine, a medication which is FDA approved to induce miosis, (in other&#xD;
      words cause the pupil to constrict or become smaller) provides additional benefit to the&#xD;
      success of Trabectome and cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma is the leading cause of irreversible blindness worldwide, and its treatment consists&#xD;
      of lowering intraocular pressure (IOP) to prevent damage to the optic nerve and loss of&#xD;
      vision. Microincisional glaucoma surgery (MIGS) have become more popular in recent years as&#xD;
      less invasive methods than traditional surgeries that effectively reduce IOP and help reduce&#xD;
      the medication burden on patients.There are multiple available MIGS procedures, most of which&#xD;
      act by increasing trabecular outflow. One such procedure is the Trabectome, which is usually&#xD;
      performed in combination with cataract surgery.&#xD;
&#xD;
      Trabectome is an FDA approved device used to perform a trabeculectomy via an internal&#xD;
      approach. A strip of 60-120 degrees of the nasal angle trabecular meshwork and the inner wall&#xD;
      of Schlemm's canal are removed providing a direct pathway for aqueous outflow from the&#xD;
      anterior chamber into the collector channels[2].&#xD;
&#xD;
      Pilocarpine, a parasympathomimetic agent, is a glaucoma medication that works by causing&#xD;
      contraction of the ciliary muscle leading to opening of the trabecular meshwork[3]. Due to&#xD;
      its frequent dosing requirement and large number of ocular and systemic side effects,&#xD;
      pilocarpine has largely fallen out of favor for the treatment of primary open angle glaucoma&#xD;
      (POAG), except in patients for whom few other alternatives exist. However, pilocarpine is&#xD;
      often used after trabectome surgery.&#xD;
&#xD;
      The rationale for its use after Trabectome procedure is for its miotic effect, which&#xD;
      theoretically may prevent the formation of peripheral anterior synechiae. Formation of&#xD;
      peripheral anterior synechiae can lead to the closure of the cleft that is generated and the&#xD;
      possibility of failure of the procedure. While the theoretical benefit of pilocarpine has&#xD;
      been proposed, its actual benefit has never been proven.&#xD;
&#xD;
      In this study, the aim is to evaluate whether Trabecome / Cataract surgery without&#xD;
      pilocarpine is non-inferior to Trabecome / Cataract surgery procedure followed by treatment&#xD;
      with pilocarpine&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    not performing Trabectomes&#xD;
  </why_stopped>
  <start_date type="Actual">June 5, 2019</start_date>
  <completion_date type="Actual">January 21, 2021</completion_date>
  <primary_completion_date type="Actual">January 21, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The &quot;Treatment Group&quot; will use 2% pilocarpine in the postoperative period in addition to standard post-operative drops (Prednisolone acetate and Ofloxacin). The &quot;Control Group&quot; will use only Prednisolone acetate and Ofloxacin, without pilocarpine.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of intraocular lowering from baseline</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Percentage of IOP drop at 1 month, 6 months and 1 year after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of IOP lowering agents required to achieve goal IOP</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The number of pre and post procedure drops required to achieve goal IOP at 6 months, 1, 2 and 3 years after combined cataract/trabectome surgery in patients treated with post-op pilocarpine vs control</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of progression to further glaucoma surgeries.</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Assessment of the rate of progression towards further surgery in patients treated with post-op pilocarpine vs control over a 3 year follow up period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of pilocarpine related side effects</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Most common side effects will be counted - blurry vision, decrease night vision, headaches, browache, nausea, vomiting, diarrhea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of drug discontinuation due to pilocarpine related side effects</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The number of drug discontinuation due to common side effects will be counted</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% pilocarpine and standard of care post op drops ( Prednisolone acetate and Ofloxacin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care post op drops-Prednisolone acetate and Ofloxacin, without pilocarpine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pilocarpine</intervention_name>
    <description>2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Ocu-Carpine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofloxacin</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Ocuflox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Ocu-Pred</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age Range: 30 to 100 years old&#xD;
&#xD;
          -  Patients with ocular hypertension or open angle glaucoma undergoing combined cataract&#xD;
             surgery with trabectome in a single surgical center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with previous history of eye surgeries (including laser procedures).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Jeng (Melissa) Yao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract surgery</keyword>
  <keyword>Trabectome</keyword>
  <keyword>Eye Surgery</keyword>
  <keyword>Vision</keyword>
  <keyword>Glaucoma Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT04005079/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

